BioSpace News Archive

CG Oncology, Inc. announced today it has triggered the first development milestone payment under its licensing agreement with Kissei Pharmaceutical Co., Ltd. for its oncology immunotherapy CG0070 for Japan South Korea, Taiwan and other Asian countries with the exception of China.

ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope ® TATX-03 Antibody Cocktail Manufacturing Collaboration.

SCYNEXIS, Inc. (NASDAQ: SCYX), today announced that BREXAFEMME® (ibrexafungerp tablets) has been added to a major national formulary, bringing total coverage for this innovative product to more than 45% of commercially insured patients in the U.S.

ALR Technologies today releases an open letter to shareholders from Chairman and Chief Executive Officer Sidney Chan.

Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici, the international research-focused pharmaceuticals and healthcare Group, welcomes the findings of an international panel of expert clinicians gathered to re-define the clinical pathways for diagnosing and classifying exacerbations of chronic obstructive pulmonary disease at the 2021 International Meeting on Asthma and COPD hosted in Florence, Italy.

OrganOx, a world leader in normothermic machine perfusion (NMP), today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of its metra system.

I believe ongoing communications with you is my responsibility; therefore, I wanted to take this opportunity to review our accomplishments over the past year and provide some insight on what we expect to come in the new year.

Arcadia Biosciences, Inc. announced it has appointed Kevin Comcowich, current Chairman of the Arcadia Board of Directors, as interim chief executive officer, effective January 1, 2022.

Texas Biomedical Research Institute’s inaugural bond sale has been named the 2021 Deal of the Year by Smith’s Research and Gradings, an investment research and analysis company.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Par Pharmaceutical, Inc. (“Par”) has unilaterally withdrawn its request that the U.S. District Court for the District of Delaware issue a temporary restraining order and preliminary injunction preventing the launch of Eagle’s recently approved vasopressin product.